We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Stock Moves -1.21%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Hologic (HOLX - Free Report) closed at $70.80, marking a -1.21% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.48%. At the same time, the Dow lost 0.46%, and the tech-heavy Nasdaq lost 3.02%.
Prior to today's trading, shares of the medical device maker had lost 13.13% over the past month. This has lagged the Medical sector's loss of 3.56% and the S&P 500's gain of 1.23% in that time.
Investors will be hoping for strength from HOLX as it approaches its next earnings release. On that day, HOLX is projected to report earnings of $2.61 per share, which would represent year-over-year growth of 357.89%. Meanwhile, our latest consensus estimate is calling for revenue of $1.54 billion, up 103.27% from the prior-year quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $8.81 per share and revenue of $5.7 billion. These results would represent year-over-year changes of +121.36% and +50.83%, respectively.
Investors should also note any recent changes to analyst estimates for HOLX. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. HOLX is currently a Zacks Rank #2 (Buy).
In terms of valuation, HOLX is currently trading at a Forward P/E ratio of 8.13. For comparison, its industry has an average Forward P/E of 41.13, which means HOLX is trading at a discount to the group.
We can also see that HOLX currently has a PEG ratio of 0.53. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 3.09 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Stock Moves -1.21%: What You Should Know
In the latest trading session, Hologic (HOLX - Free Report) closed at $70.80, marking a -1.21% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.48%. At the same time, the Dow lost 0.46%, and the tech-heavy Nasdaq lost 3.02%.
Prior to today's trading, shares of the medical device maker had lost 13.13% over the past month. This has lagged the Medical sector's loss of 3.56% and the S&P 500's gain of 1.23% in that time.
Investors will be hoping for strength from HOLX as it approaches its next earnings release. On that day, HOLX is projected to report earnings of $2.61 per share, which would represent year-over-year growth of 357.89%. Meanwhile, our latest consensus estimate is calling for revenue of $1.54 billion, up 103.27% from the prior-year quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $8.81 per share and revenue of $5.7 billion. These results would represent year-over-year changes of +121.36% and +50.83%, respectively.
Investors should also note any recent changes to analyst estimates for HOLX. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. HOLX is currently a Zacks Rank #2 (Buy).
In terms of valuation, HOLX is currently trading at a Forward P/E ratio of 8.13. For comparison, its industry has an average Forward P/E of 41.13, which means HOLX is trading at a discount to the group.
We can also see that HOLX currently has a PEG ratio of 0.53. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 3.09 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.